Oxford Technology 2 VCT Faces NAV Decline Amid Market Challenges

Pick the best stocks and maximize your portfolio:

An update from Oxford Technology 2 VCT ( (GB:OXH) ) is now available.

Oxford Technology 2 VCT Plc reported a decline in its net asset value for the quarter ending 30 November 2024, primarily due to decreased valuations of its key AIM quoted investments, Scancell Holdings and Arecor Therapeutics. Despite Scancell’s successful fundraising and new partnerships, the market has not reflected these positive developments. The company also faced a setback with Novacta Holdings entering administration, prompting a full provision against this investment. Meanwhile, Biocote Limited showed improved performance with increased sales. The board resolved concerns regarding remuneration policy with a major shareholder, indicating improved governance. The company did not declare dividends or engage in share transactions during the period.

More about Oxford Technology 2 VCT

Oxford Technology 2 VCT Plc operates within the venture capital trust industry, focusing on investments in early-stage technology companies. The company’s portfolio includes quoted and unquoted investments in sectors like healthcare and biotechnology, with a particular focus on AIM-listed firms.

YTD Price Performance: -58.82%

Technical Sentiment Consensus Rating: Buy

For a thorough assessment of OXH stock, go to TipRanks’ Stock Analysis page.

Trending Articles

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.